News & Events
Wednesday, January 12, 2022 (EST), Newave Pharmaceuticals presented at the 40th Annual J.P. Morgan Healthcare Conference. Dr. Stephen Anthony, the CMO of US/EU/UK Oncology Operation, gave a presentation on behalf of the company. Dr. Anthony shared the fast-growth of Newave in the past few years, including the key milestones achieved in several projects and the development of an innovative anti-cancer pipeline, which attracted the attention of many domestic and international companies.
As a clinical-stage company, Newave is committed to focus on the drug discovery and development of novel therapies for cancer treatment. Newave’s drug design team is dedicated to the rational drug design with strong differentiations. Our three strategic R&D platforms (Small Molecule, Protein Degrader and Antibody Drug Conjugate) rapidly advanced a rich and innovative pipeline, five of which are now undergoing clinical trials in China, the United States and Europe. There are also several projects under different stages from drug design to pre-clinical development. More and more projects will move forward into clinical trials over the ensuing years. And Newave owns the global right of all properties and assets.
In this meeting, Dr. Anthony mainly introduced the research progress of LP-108 and LP-118:
About LP-108:
LP-108 is a highly potent, oral and selective Bcl-2 inhibitor, which is comparable to Venetoclax. It shows an excellent tumor growth suppression in preclinical vitro enzymatic study and various vitro and vivo hematological models.
Now LP-108 is undergoing phase I clinical trial in both China and the U.S., aiming to evaluate safety, tolerability, PK and preliminary efficacy on patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma in China, and patients with relapsed or refractory MDS, CMML, or AML in the U.S. Now both two trials have completed several cohorts enrollment. All patients tolerated LP-108 well, no TLS or DLT observed. Phase Ib study of LP-108 has been activated in multi-centers in China, and the U.S. and Europe are also under the preparation of phase Ib study.
About LP-118:
LP-118, a newest-generation, highly potent, oral and selective BCL-2 inhibitor with tuned Bcl-xL activity, overcoming Venetoclax resistant mutations such as G101V, A113G, or D103Y. LP-118 shows an excellent efficacy in preclinical vitro enzymatic study and various tumor animal models over Venetoclax. It also exhibits a good safety profile and PK.
Clinical studies are conducted in China and the US, to assess the safety, tolerability, PK, MTD and DLTs in adult patients with advanced malignancies, as well as to determine the recommended doses for late clinical studies.
About Dr. Stephen Anthony:
Dr. Anthony graduated from Philadelphia College of Osteopathic Medicine. Board certified expert in Hematology and Oncology. He has over 24 years of clinical practice in private and academia, and also has over 20 papers and dozens of abstracts published in high impact and quality journals such as J.Clin. Oncol, Nat. Genet., Clin. Cancer Res, etc. His prior roles include MD, clinical medicine VP and CMO in Pfizer, Amgen, Tolero, Arizona Oncology, Evergreen Hematology and Oncology. He was involved and responsible for more than 200 global clinical trials from phase I to phase III. He joined Newave in 2020, and now leading U.S./Europe medical group to develop LP-108, LP-118 and LP-168 clinical trials.
About JPM Healthcare Conference:
JPM healthcare conference is the largest, most informative and influential health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
About Newave:
We are a clinical-stage company mainly focused on the drug discovery & development of novel therapies for cancer treatment. We have a world-class MedChem team, mainly pursue clinically validated targets with significant unmet needs, challenging medicinal chemistry, and strong interests from big pharma, particularly the targets with strong synergy with Bcl-2 pathway. Our drug design team dedicate to the rational drug design of proprietary drug candidates with strong differentiations. Our clinical teams have deep understanding and rich experience in rapid and cost-effective completion of clinical proof-of-concept (POC) and pivotal studies both in China and US. We strive to bring newest generation medicines to cancer patients worldwide.